New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
16:10 EDTACTActavis announces Nuvigil patent challenge settlement
Actavis announced that it has entered into an agreement with Cephalon to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil. Nuvigil is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder or narcolepsy. Under the terms of the agreement, Cephalon will grant Actavis a license to market generic versions of 100 mg and 200 mg Nuvigil beginning on June 1, 2016, or earlier under certain circumstances. Cephalon will also grant Actavis a license to market generic versions of 50 mg, 150 mg and 250 mg Nuvigil beginning 180 days after the initial launch of generic versions of those dosage strengths. Other details of the settlement were not disclosed. Based on available information, Actavis believes it is a "first applicant" to file an ANDA for the generic versions of 100 mg and 200 mg Nuvigil and expects to be entitled to 180 days of generic market exclusivity.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2015
06:18 EDTACTActavis urges U.S. appeals court to reverse decision on Namenda, AP reports
Subscribe for More Information
April 13, 2015
16:37 EDTACTActavis announces availability of 52mg Liletta to prevent pregnancy
Actavis and Medicines360, a nonprofit women's health pharmaceutical company, announced that Liletta 52 mg is now available in the U.S. for use by women to prevent pregnancy for up to three years.
10:52 EDTACTMeister says Actavis bought great companies, can continue growing
Subscribe for More Information
09:27 EDTACTActavis and Medicine360 announce Liletta es available in the U.S.
Subscribe for More Information
08:34 EDTACTZoetis names Actavis Executive Chairman Paul Bisaro to board
Subscribe for More Information
April 9, 2015
11:39 EDTACTPershing Square, Valeant, Allergan drop lawsuit over buyout
Subscribe for More Information
April 8, 2015
09:16 EDTACTActavis COPD drug Daliresp gets Paragraph 4 challenge
Subscribe for More Information
08:05 EDTACTActavis price target raised to $348 from $328 at Leerink
Subscribe for More Information
08:04 EDTACTActavis potential acquisition Rhythm initiates Phase 2b study of relamorelin
Subscribe for More Information
07:34 EDTACTActavis initiates Phase 2b clinical trial of relamorelin
Subscribe for More Information
April 5, 2015
14:43 EDTACTActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use